Introduction
RNA interference (RNAi) shows considerable promise as a therapeutic approach to silence disease-causing genes, in particularly for so-called 'non-druggable' targets that are not amenable to conventional therapeutics such as small molecules and monoclonal antibodies (mAbs). 1 To date, systemic [2] [3] [4] [5] [6] and mucosal [7] [8] [9] delivery of small-interfering RNAs (siRNAs) as well as subretinal applications 10 have been successful, and several clinical trials are underway using intraorbital eye injections and nebulized delivery to lung. Diseases of the skin, especially those with defined molecular targets, are also amenable to nucleic-acid-based therapies due to tissue accessibility. 11, 12 However, although a number of methods have showed limited delivery of nucleic acids to skin, normal skin represents a formidable barrier to topical delivery of negatively charged biomolecules. [13] [14] [15] [16] [17] Furthermore the current methods for local administration of siRNAs are not patient friendly and/or do not deliver physiologically relevant levels to target tissues.
Osteopontin (OPN) is an extracellular matrix cytokine that has been originally identified as the predominant transcript in activated T lymphocytes, 18, 19 and is now known to have pleiotropic functions, including proinflammatory activities. 20, 21 OPN is classified as a Th1 cytokine because of its ability to enhance the production of interferon-g and interleukin (IL)-12 in macrophages 20 and has been shown to have a pivotal function in the pathogenesis of rheumatoid arthritis (RA). 22, 23 Indeed, specific antisera (M5 Ab) raised against the OPN-specific peptide sequence SLAYGLR significantly suppress the development of collagen antibody-induced arthritis in mice. 24 In addition, a recent study suggests the secreted form of OPN exerts opposing effects on mouse T helper 2 effecter responses and subsequent allergic airway disease. 25 Taken together, these data suggest that OPN is an important therapeutic target for inflammatory diseases.
In this study, we demonstrate the effectiveness of a new siRNA delivery method using a cream formulation GeneCream that facilitates siRNA transport into the skin and subcutaneous tissues. We examined the effects of the OPN siRNA cream in a mouse RA model, in which symptoms are induced by anti-type II collagen mAbs, and found that the siRNA cream significantly and reproducibly suppressed the development of arthritic symptoms. Because this technology does not require viral vectors, needles or electroporation, it represents a safe and promising patient-friendly strategy for RA therapy, and is also expected to be applicable to other various skin diseases.
Results

siRNA cream penetrates into the dermis
Although normal skin (the stratum corneum) is considered to be the main barrier to percutaneous absorption, it is also regarded as the main pathway for penetration. 26 GeneCream a lipid/alcohol-based formulation (TransDerm Inc., Santa Cruz, CA, USA), was evaluated for its ability to deliver siRNAs to mouse skin. Following incubation times of 0, 1, 2, 4 and 10 h after application of cream containing a non-silencing control siRNA to mouse skin, in situ hybridization was performed using a specific cognate locked nucleic acid (LNA) probe 27, 28 to monitor siRNA penetration through the skin. Control siRNA was detected in the epidermis at 1 h, in dermis at 4 h and in fat tissue of the subcutis 10 h after cream application (Figure 1 ). However, we did not observe any hybridization signals in the tissue sections from the siRNA cream-treated mouse without probes and of the no siRNA-treated mouse with the probe (Figure 1 ). These data suggest that the cream can deliver siRNA, not only to the dermis, but also to the subcutis in mouse skin.
OPN siRNA cream blocks onset of symptoms in a murine RA model Yamamoto et al. 24 have shown that a specific OPN antibody suppresses the development of type II collagen antibody-induced arthritis in mice. Thus, to examine whether the cream containing OPN siRNA can suppress the development of arthritis in mice, type II collagen antibody-induced arthritic mice were treated with the OPN siRNA cream daily beginning 1 week before injection of the arthritis inducer, a collagen antibody (Figure 2a ). Figure 2a shows that topical administration of the OPN siRNA cream led to attenuate the severity of arthritis. The gross appearance of arthritic joints in the OPN siRNA cream-treated mice was similar to that of normal mice (Figure 2b ). Next the effect of the OPN siRNA cream on joint histology was examined on day 6 after lipopolysaccharide (LPS) injection (Figure 2b) . The significant suppression of synovial hyperplasia (Po0.05; Figure 2c ), leukocyte infiltration (mainly polymorphonuclear leukocytes) (Po0.05; Figure 2d ) and erosion of joint cartilage (Po0.05; Figure 2e ) was evident in the OPN siRNA cream-treated mice. In addition, to investigate whether the OPN siRNA cream improves symptoms of the arthritic mouse, type II collagen antibodyinduced arthritic mice were also treated with the OPN siRNA cream daily beginning 1 week posterior to injection of the collagen antibody (Figure 2f ). Therapeutic silencing by siRNA cream M Takanashi et al mice ( Figure 3a) . Next, the expression of OPN was confirmed in hind paws by quantitative real-time PCR analysis. To evaluate the penetration of the siRNA cream, we isolated mRNA separately from 'bone and muscle' and 'skin and subcutaneous tissue' of the ankle joint. The OPN siRNA cream suppressed the OPN mRNA levels ninefold in the skin and subcutaneous tissue as determined by realtime PCR (Figure 3b ). Importantly, no significant differences were observed in the bone and muscle between the control and the OPN siRNA cream-treated mice ( Figure  3b ). Furthermore, OPN protein levels were examined in the serum of the siRNA-treated mice injected with the type II collagen antibody and LPS. Topical application of the OPN siRNA cream reduced serum OPN protein levels to 1.68±0.59 mg ml À1 (n ¼ 6), as compared to 2.28 ± 0.36 mg ml À1 in serum from the untreated mice (n ¼ 6) and 2.22±0.72 mg ml À1 in serum from the scramble siRNA cream-treated control mice (n ¼ 6) (Figure 3c ). These results suggest that the induction of OPN is significantly reduced at both mRNA and protein levels in type II collagen antibody-induced arthritic mice by the OPN siRNA cream.
OPN siRNA cream suppresses migration of T cells and macrophages in synovitis
OPN has previously been reported to have a central function in the activation and migration of T lymphocytes. 23 Therefore, to examine the ability of the OPN siRNA cream to suppress accumulation of T lymphocytes and macrophages in the synovitis of collagen antibody-induced arthritis mice, we performed immunohistochemical analysis using anti-CD3 and CD68 antibodies. A decreased number of CD3-and CD68-positive cells in the synovium of mice treated with the OPN siRNA cream was observed (Figure 4) . These results show that the OPN siRNA cream mediated the depletion of OPN in type II collagen antibodyinduced arthritis, leading to a decreased accumulation of T lymphocytes and macrophages, consequently resulting in suppression of disease.
Discussion
The skin is a uniquely attractive tissue for investigation of RNAi therapeutic approaches due to its accessibility as well as the fact that there are large numbers of diseases amenable to cutaneous gene mediation. Many studies have demonstrated in vivo gene silencing in skin with RNAi including delivery through direct intradermal injection, 29 an agarose matrix system 30 and electroporation. 17 However these approaches have limited potential for translation to the clinic. In this report, we demonstrate effective siRNA delivery using topically administered cream. This approach is noninvasive and represents a breakthrough that may result in a patientfriendly product that could potentially be applied in a home-based setting. The efficacy of the siRNA cream is demonstrated by the ability of the OPN siRNA cream to ameliorate symptoms in the RA mouse model. In addition to confirming that the siRNA cream penetrates into the fat tissue in dermis (Figure 1 ), the OPN siRNA was shown to suppress the OPN gene expression in the skin and subcutaneous tissue (Figure 3b ). These results suggest that this cream may be effective not only for disorders of the epidermis, but also for dermal disorders. Furthermore, we also carried out a successful hormone delivery to the blood with GeneCream on other areas of the mouse body such as back skin (data not shown), suggesting that the siRNA cream applied to various areas of the skin as a whole penetrates into the fat tissue in dermis. Although skin of mice may be different from that of larger animals, we have not examined the effects of the siRNA cream on larger animal models yet because collagen-induced arthritis occurs only in mouse at present. Additional studies are required to assess the feasibility of siRNA utilization in clinical settings.
Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic joint inflammation and destruction. Cytokines including tumor necrosis factor-a (TNF-a), IL-1b, IL-6, IL-17 and OPN have key functions in driving synovial cell activation leading to joint destruction in RA. 24, [31] [32] [33] Recently, biologics including TNF-a, IL-1b and IL-6 antagonists have shown efficacy as RA therapeutics. [34] [35] [36] [37] [38] However, these treatments result in increased risks for a variety of infectious diseases (such as tuberculosis), malignancy and other adverse outcomes, 39, 40 raising concerns about the use of currently available biologics, particularly anti-TNF-a agents. In addition, these biologics often require combination treatment with conventional disease-modifying antirheumatic drugs, in particular methotrexate (MTX) for effective treatment of RA. 41 Approximately 30% of patients, however, abandoned the MTX treatment be- Therapeutic silencing by siRNA cream M Takanashi et al cause of its unacceptably high drug-related side effects. 42, 43 Thus, additional RA treatments are needed, and siRNA-based therapeutics are excellent therapeutic candidates for treating RA, particularly because they can be effectively delivered by topical formulations such as siRNA cream.
In summary, RNAi-based therapeutics are poised to offer unprecedented specificity to inhibit disease-causing genes. The identification of a suitable delivery vehicle, such as siRNA cream, represents a promising step forward in translation to the clinic of siRNA-based drugs for treatment of skin disorders and subcutaneous tissue inflammation.
Materials and methods
All animal studies conformed to the Tokyo Medical University Institutional Animal Care and Use Committee guidelines.
Delivery vehicle and siRNA sequences
GeneCream (patent pending; contains a lipid/alcohol base) formulated with the OPN siRNA (1 mg ml À1 ) was provided by TransDerm Inc. The cream containing siRNA was stored at 4 1C and used within 2 months after the manufacture.
Target sequences for the OPN siRNAs were used as previously described. 44 The siRNA sequences used in this study were as follows: OPN siRNA (sense, 5
0 -GCCA UGACCACAUGGACGAdTdT-3 0 ; antisense, 5 0 -dTdTCG GUACUGGUGUACCUGCU-3 0 ), non-silencing scramble siRNA (sense, 5 0 -CGGUAACAACGCGUACACGdTdT-3; antisense, 5 0 -dTdTCGTGTACGCGTTGTTACCG-3 0 ).
In situ hybridization
To evaluate the ability of GeneCream to penetrate the stratum corneum and deliver siRNAs to the epidermis, dermis and subcutis, we topically applied GeneCream containing a scramble siRNA to the shaved backs of 7-week-old female Balb/c mice (Japan SLC, Shizuoka, Japan) at the dose of 2 mg per body. Following incubation times ranging from 0 to 10 h, the mice were killed, and the skins of the mice were excised and fixed with a neutral buffered formalin and embedded in paraffin. In situ hybridization was performed using the RiboMap in situ hybridization kit (Ventana Medical Systems, Tucson, AZ, USA) on the Ventana Discovery automated in situ hybridization instrument (Ventana Medical Systems). The biotin-labeled, LNA-modified DNA probe against the scramble siRNA was obtained from Exiqon (Exiqon, Vedbaek, Denmark). The in situ hybridization steps after the deparaffinization step were performed according to the manufacturer's RiboMap (http://www.ventanamed.com) application note. The initial fixation step was performed by incubating the sections in formalin-based RiboPrep reagent (Ventana Medical Systems) for 30 min at 37 1C. After acid treatment using hydrochloride-based RiboClear reagent (Ventana Medical Systems) for 10 min at 37 1C, the slides were treated with the ready-to-use protease 2 reagent. The sections were hybridized with the anti-sense LNA riboprobe (2 ng per slide) using RiboHybe hybridization buffer (Ventana Medical Systems) for 6 h at 37 1C after an initial denaturing pre-hybridization step for 6 min at 70 1C. After a low stringency wash with 2 Â RiboWash (equivalent to 0.2 Â standard saline citrate; Ventana Medical Systems) for 6 min at 42 1C, a second washing step was performed using 1 Â RiboFix reagent for 20 min at 37 1C followed by incubation of biotin-labeled antidigoxigenin antibody (Sigma, St Louis, MO, USA) for 30 min at 37 1C. After incubating the streptavidin-alkaline phosphatase conjugate for 16 min at 37 1C, we detected signal using the BlueMap NBT/BCIP substrate kit for 4 h at 37 1C. Finally, the sections were counterstained with Kernechtrot as a marker stain and covered with a glass coverslip.
Induction and clinical assessment of arthritis in mice
Arthritis was induced by administration of an arthritogenic mAb cocktail kit (Arthrogen-CIA mAb; ImmunoBiological Laboratories, Takasaki, Japan). Briefly, 7-weekold female Balb/c mice were injected intraperitoneally with a mixture of four anti-type II collagen mAbs (2 mg per body) on day 0 followed by intraperitoneal injection with 100 mg of LPS on day 2. 45 The OPN siRNA cream was topically applied to the paws of mice at a dose of 2 mg per body daily, beginning 1 week prior or posterior to injection of anti-type II collagen mAbs. The control group was administrated with the scramble siRNA cream at a dose of 2 mg per body in similar manner to the OPN siRNA cream treatment. The clinical severity of arthritis was graded in each of the two hind paws on a 1-3 scale as described previously. 24 The disease severity was recorded for each limb as follows: 0, normal; 1, slight swelling and/or redness in one joint; 2, moderate swelling in the entire paw and 3, deformity and/or ankylosis.
Histology
Histological assessment of the arthritic joint of ankles on day 8 was performed by staining with hematoxylin and eosin. The degrees of synovial proliferation, leukocyte infiltration and cartilage degeneration were graded as follows: 0, normal; 1, mild proliferation of synovium and minor leukocyte infiltration into synovium or minor erosion of the cartilage; 2, invasion of synovium into the joint space and moderate leukocyte infiltration or mild pannus erosion of the cartilage; and 3, extensive leukocyte infiltration into the joint space, fibrous ankylosis of the joints and peripheral and subchondral cartilage erosion.
Immunohistochemistry
Immunohistochemistry for OPN (anti-mouse osteopontin polyclonal antibody, AF808; R&D Systems, Minneapolis, MN, USA), CD3 (anti-CD3 polyclonal antibody, A0452; Dako, Glostrub, Denmark) and CD68 (KP-1, M0814; Dako) was performed in formalin-fixed, paraffin-embedded tissues. All slides were stained using the Ventana HX System Benchmark (Ventana Medical Systems). To evaluate the CD3-positive cells, we carried out photography at a magnification of Â 200 with a digital camera DP70 (Olympus, Tokyo, Japan), and the number of positive cells in a field was counted.
Expression analysis of OPN
Total RNAs from the ankle joints and skin were extracted using Isogen (Nippon Gene, Tokyo, Japan). Quantitative real-time PCR was performed using specific primer The concentration of OPN protein in RA mouse serum was measured quantitatively using the Mouse Osteopontin Quantikine ELISA kit (R&D Systems) according to the manufacturer's procedure.
Statistical analysis
Statistical evaluation was performed on the basis of Student's t-test or Welch's t-test. P-values less than 0.05 were considered significant.
